Another Alzheimer’s blood test gets OK from FDA | CNN

The US Food and Drug Administration has cleared Roche and partner Eli Lilly’s blood test to help ​identify signs of Alzheimer’s disease in people age ‌55 and older with cognitive decline. The test, Elecsys pTau217, is a biomarker blood test that can help doctors identify patients who are ​likely or unlikely to have Alzheimer’s-related brain changes, ​Roche said Monday. The FDA clearance follows European ⁠approval for the test in May. The test can be ​run on more than 4,500 Roche laboratory analyzers already installed ​across the United States, which the company said could help broaden access. Labcorp and Quest Diagnostics have said they plan to offer ​the test through their laboratory networks, potentially expanding availability. Roche did not disclose the test’s price. The FDA clearance ​comes as ⁠drugmakers and diagnostic companies race to develop simpler tests for Alzheimer’s disease to meet growing ​demand for earlier diagnosis and treatment. Fujirebio’s Lumipulse became ​the ⁠first blood test cleared by the FDA to aid in the assessment of Alzheimer’s disease in 2025. Roche and Lilly’s Elecsys pTau181 test, which measures a different pr

Aug 24, 2026 → Aug 24, 2026